Biologic classification as an alternative to anatomic staging for clinically localized prostate cancer: A proposal based on patients treated with external beam radiotherapy

Urology

Volumn 51, Issue 2, 1998, Pages 265-270

  Ennis, Ronald D ^a   Malyszko, Bozena K ^a   Rescigno, John ^a   Whitman, Adam E ^a   Heitjan, Daniel F ^a   O'Toole, Kathleen M ^a   Rubin, Mark ^a   Schiff, Peter B ^a  

^a The New York Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; TRANSURETHRAL RESECTION;

ADENOCARCINOMA; DISEASE-FREE SURVIVAL; HUMANS; MALE; NEOPLASM STAGING; PROGNOSIS; PROSTATIC NEOPLASMS;

EID: 0032005398     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00503-7     Document Type: Article

References (21)

1. Hermanek P, Sobin LH, Fleming ID. What do we need beyond TNM? Cancer. 77:1996;815-817.
2. Bearhs OH, Henson DE, Hutter RVP, Myers MH. 3rd ed. Manual for Staging of Cancer. 1988;177-182 Lippincott, Philadelphia.
3. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ. 4th ed. Manual for Staging of Cancer. 1992;181-186 Lipincott, Philadelphia.
4. Epstein JI, Pizov G, Walsh PC. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer. 71:1993;3582-3593.
5. Catalona WJ, Smith DS. Five year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol. 152:1994;1837-1842. (5 Pt 2).
6. Paulson DF, Moul JW, Walther PJ. Radical prostatectomy for clinical stage T1-2N0M0 prostatic adenocarcinoma: long-term results. J Urol. 144:1990;1180-1184.
7. Middleton RG, Thompson IM, Austenfeld MS, Cooner WH, Correa RJ, Gibbons RP, Miller HC, Oesterling JE, Resnick MI, Smalley SR, et al. Prostate Cancer Clinical Guidelines Panel summary report on the management of clinically localized prostate cancer. J Urol. 154:1995;2144-2148.
8. Oesterling JE, Movad MA, Wright GL, Beck GR. An analytical comparison of the three most commonly used prostate-specific antigen assays: Tandem-R, Tandem-E, and IMx. Urology. 46:1995;524-532.
9. Oesterling JE, Martin SK, Bergstralh EJ, Lowe FC. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA. 269:1993;57-60.
10. Zentner PG, Pao LK, Benson MC, McMahon DJ, Schiff PB. Prostate-specific antigen density: a new prognostic indicator for prostate cancer. Int J Radiat Oncol Biol Phys. 27:1993;47-58.
11. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 37:1997;1035-1041.
12. Zietman AL, Coen JJ, Shipley WU, Willett CG, Efird JT. Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. J Urol. 151:1994;640-645.
13. Lee WR, Hanks GE, Schultheiss TE, Corn BW, Hunt MA. Localized prostate cancer treated by external-beam radiotherapy alone: serum prostate-specific antigen-driven outcome analysis. J Clin Oncol. 13:1995;464-469.
14. Zagars GK, Pollack A, vonEschenbach AC. Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era. Cancer. 79:1997;1370-1380.
15. Pisansky TM, Kahn MJ, Rasp GM, Cha SS, Haddock MG, Bostwick DG. A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate carcinoma. Cancer. 79:1997;337-344.
16. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, Walsh PC. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 150:1993;110-114.
17. Kleer E, Larson-Keller JJ, Zincke H, Oesterling JE. Ability of preoperative serum prostate-specific antigen value to predict pathologic stage and DNA ploidy. Influence of clinical stage and tumor grade. Urology. 41:1993;207-216.
18. Platt JF, Bree RL, Schwab RE. The accuracy of CT in the staging of carcinoma of the prostate. AJR Am J Roentgenol. 149:1987;315-318.
19. Rifkin MD, Zerhouni EA, Gastonis CA, Quint LE, Paushter DM, Epstein JI, Hamper U, Walsh PC, McNeil BJ. Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial. N Engl J Med. 323:1990;621-626.
20. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Schnall M, Tomaszewski JE, Wein A. Critical analysis of the ability of the endorectal coil magnetic resonance imaging scan to predict pathologic stage, margin status, and postoperative prostate-specific antigen failure in patients with clinically organ-confined prostate cancer. J Clin Oncol. 14:1996;1770-1777.
21. Kantoff PW, Talcott JA. The radical prostatectomy series: apples are not oranges. J Clin Oncol. 12:1994;2243-2245.